SOURCE: Cell Genesys, Inc.

March 20, 2008 08:30 ET

Cell Genesys to Present at the 15th Annual Future Leaders in the Biotech Industry Conference

SOUTH SAN FRANCISCO, CA--(Marketwire - March 20, 2008) - Cell Genesys, Inc. (NASDAQ: CEGE) today announced that Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will present a company update at the 15th Annual Future Leaders in the Biotech Industry Conference in New York City on Thursday, March 27, 2008 at 10:00 a.m. ET.

A live audio webcast of the presentation will be accessible through the Investor Relations section of the Cell Genesys website, www.cellgenesys.com. If you are unable to listen to the live webcast, it will be archived on the site for at least 72 hours following the presentation. To access the replay, go to the Investor Relations section of the website.

Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX™ cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at www.cellgenesys.com.

Contact Information


  • Contact:
    Susan Ferris
    Investor Relations
    650-266-3200